SpringWorks Therapeutics, Inc.
SWTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
SWTX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Nirogacestat oral tablet
Desmoid Tumor
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Plexiform Neurofibroma
Nirogacestat
Ovarian Granulosa-Stromal Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nirogacestat oral tablet | Phase 3 | Desmoid Tumor | - | - |
Mirdametinib (PD-0325901) oral capsule or dispersible tablet | Phase 2 | Plexiform Neurofibroma | - | - |
Nirogacestat | Phase 2 | Ovarian Granulosa-Stromal Tumor | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply